Table 1. Behaviour of Proclarix, and univariate analysis regarding to clinical characteristics of the study population and its pathologic features.
| Characteristic | Men | Proclarix (%) | p-value | |
|---|---|---|---|---|
| Biopsy result | 567 (100.0) | |||
| Benign | 271 (47.8) | 21.3 (9.5–34.6) | - | |
| Prostate cancer | 296 (52.2) | 39.6 (24.9–65.7) | <0.001a | |
| Grade group in biopsy | 296 (100.0) | |||
| 1 | 66 (22.3) | 26.6 (14.6–40.6) | 0.026a | |
| 2 | 87 (29.4) | 39.1 (23.2–56.0) | <0.001 | |
| 3 | 61 (20.6) | 38.4 (25.5–53.6) | 0.861 | |
| 4 | 51 (17.2) | 53.6 (31.2–51.0) | 0.018 | |
| 5 | 31 (10.5) | 74.5 (46.3–98.0) | 0.047 | |
| Clinical stage (TNM) | 296 (100.0) | |||
| Localized (cT1-2 N0 M0) | 263 (88.9) | 37.3 (22.6–57.1) | <0.001a | |
| Locally advanced (cT3-4 N0 M0) | 22 (7.4) | 60.1 (36.1–94.9) | <0.001 | |
| Disseminated (cT1-4 N0-1 M0-1) | 11 (3.7) | 97.4 (51.6–100) | <0.001 | |
| Localized prostate cancer recurrence risk | 263 (100.0) | |||
| Low | 56 (21.3) | 24.8 (14–4–37.7) | 0.198a | |
| Intermediate | 136 (51.7) | 34.1 (23.6–53.4) | <0.001 | |
| High | 71 (27.0) | 57.3 (31.4–80.9) | <0.001 | |
| Type of prostate cancer | 296 (100.0) | |||
| Insignificant | 66 (22.2) | 26.5 (14.6–40.6) | 0.024a | |
| Clinically significant | 230 (77.8) | 45.8 (28.3–70.5) | <0.001 | |
| Type of pathology | 80 (100.0) | |||
| Favorable | 8 (10.0) | 14.9 (6.1–38.7) | 0.258a | |
| Unfavorable | 72 (90.0) | 30.3 (20.0–47.2) | 0.048 | |
Values presented as number (%) or median (interquartile range).
ap-value referred to benign biopsy result.